Being well aware of the important contribution that these biomarkers would have on the management of the SARS-CoV-2 infected patient, we set out to evaluate and compare the prediction efficiency of CRP, the best described biomarker during the COVID-19 pandemic, with the more recent reported modulators with pro-inflammatory (such as suPAR, MCP-1, IL-1β, IL-6, NLR, platelet-lymphocyte ratio (PLR), ESR, ferritin, fibrinogen, and LDH) and anti-inflammatory (sTREM-1 and HGF) properties in a group of patients confirmed with SARS-CoV-2 infection and stratified as mild, moderate and severe cases. Here, IL6 is linked to COVID-19.